6617 fundamentals

Gongwin Biopharm Holdings Co., Ltd. engages in the operation of Minimally Invasive Targeted Tumor Ablation business. It is a technology of minimally invasive treatment and can be directly applied to the treatment of various solid malignant tumors. Its products include PTS Minimally-Invasive Targeted Ablation and anti-tumor for canine used such as superficial malignant tumor in canine, malignant melanoma of the canine, lipoma of the canine and feline, and malignant bladder tumor of the canine and feline. The company was founded by John Wu and Rocky Shih on March 27, 2014 and is headquartered in Taipei, Taiwan.